Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mult Scler ; 14(7): 992-4, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18573826

ABSTRACT

OBJECTIVE: To evaluate whether Constraint-Induced Movement therapy (CI therapy) may benefit chronic upper extremity hemiparesis in progressive multiple sclerosis (MS). METHODS: Five patients with progressive MS, who had chronic upper extremity hemiparesis and evidence for learned non-use of the paretic limb in the life situation, underwent 30 hours of repetitive task training and shaping for the paretic limb over 2-10 consecutive weeks, along with physical restraint of the less-affected arm and a "transfer package" of behavioral techniques to reinforce treatment adherence. RESULTS: The patients showed significantly improved spontaneous, real-world limb use at post-treatment and 4 weeks post-treatment, along with improved fatigue ratings and maximal movement ability displayed in a laboratory motor test. Conclusions The findings suggest for the first time that slowly progressive MS may benefit from CI therapy. Further studies are needed to determine the retention of treatment responses.


Subject(s)
Motor Activity , Multiple Sclerosis, Chronic Progressive/rehabilitation , Paresis/rehabilitation , Physical Therapy Modalities , Activities of Daily Living , Fatigue/rehabilitation , Fatigue/therapy , Female , Humans , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/therapy , Paresis/therapy , Pilot Projects
2.
Eur J Pharmacol ; 345(1): 97-101, 1998 Mar 12.
Article in English | MEDLINE | ID: mdl-9593600

ABSTRACT

This study examined the pharmacological characteristics of binding sites for the potent K+ channel opener [3H]P1075, as well as the functional effects of P1075 on ionic currents and membrane potential, in ovine choroid plexus (OCP) cells. [3H]P1075 bound to OCP cells with a Kd of 26 +/- 4 nM and a Bmax of 10400 +/- 480 sites/cell. Labelled sites were stereoselective and inhibited by potassium channel openers with a rank order of potency: P1075 > BMS-182264, ((4-[[9cyanoimino)[(1,2,2-trimethylpropyl)amino]-methyl]amino]benz onitrile) > pinacidil >> nicorandil > diazoxide. The K(ATP) channel antagonist glyburide inhibited [3H]P1075 binding with a Ki of 2 microM. The presence of K(ATP) channels on OCP cells was examined by patch clamp and fluorescent (membrane-potential sensitive dye) techniques. In some cells, P1075 activated an outward potassium current which was blocked by glyburide. P1075 produced a glyburide-sensitive, concentration-dependent, hyperpolarization of OCP cells. Levcromakalim hyperpolarized more strongly than its 3R,4S enantiomer, BRL 38226 ((3R-trans)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)- 2H-1-benzopyran-6-carbonitrile) indicating a stereoselective interaction. These data indicate that epithelial OCP cells contain glyburide-sensitive K(ATP) channels.


Subject(s)
Choroid Plexus/metabolism , Guanidines/pharmacology , Potassium Channels/metabolism , Pyridines/pharmacology , Vasodilator Agents/pharmacology , Adenosine Triphosphate/metabolism , Animals , Binding Sites/drug effects , Cells, Cultured , Choroid Plexus/drug effects , Electrophysiology , Kinetics , Membrane Potentials/drug effects , Patch-Clamp Techniques , Potassium Channel Blockers , Potassium Channels/agonists , Sheep
4.
Mol Pharmacol ; 52(3): 473-81, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9281610

ABSTRACT

[3H]P1075 binding to membrane preparations of rabbit skeletal muscle were observed in the presence of nucleotide triphosphates or diphosphates but not AMP, cAMP, adenosine, tripolyphosphate, or pyrophosphate. Nonhydrolyzable or poorly hydrolyzable ATP analogs inhibited MgATP-supported binding. The EC50 value for MgATP-supported binding (0.4 mM) was decreased approximately 10-fold in the presence of an ATP-regenerating system, and significant metabolism by membrane nucleotidases was confirmed by high performance liquid chromatographic analysis. [3H]P1075 bound to skeletal muscle with a Kd value of 37 +/- 3 nM and a Bmax value of 280 +/- 14 fmol/mg of protein. [3H]P1075 binding to subcellular fractions was highest in membranes enriched in T tubules. Specific binding was reversible, trypsin-sensitive, maximal at pH 8, and stereoselective for the (3S,4R)-enantiomer of cromakalim. Potassium channel openers exhibited a rank order of potency of P1075 > pinacidil > levcromakalim = BMS-180448 > nicorandil > diazoxide = BRL 38226. Fluorescein analogs (ethyleosin, phloxine B, and rose bengal) were relatively potent inhibitors of binding (Ki = 200-300 nM). The potassium channel openers cromakalim and BMS-180448 were competitive inhibitors of [3H]P1075 binding. In contrast, rose bengal and the ATP-regulated potassium channel antagonist glyburide increased the rate of [3H]P1075 dissociation in a manner consistent with noncompetitive interaction.


Subject(s)
Guanidines/metabolism , Muscle, Skeletal/metabolism , Nucleotides/pharmacology , Potassium Channels/drug effects , Pyridines/metabolism , Vasodilator Agents/metabolism , Adenosine Triphosphate/pharmacology , Animals , Binding Sites , Binding, Competitive , Fluoresceins/metabolism , Fluoresceins/pharmacology , Fluorescent Dyes/metabolism , Fluorescent Dyes/pharmacology , Guanidines/pharmacology , Hydrogen-Ion Concentration , Kinetics , Membranes/metabolism , Muscle, Skeletal/drug effects , Potassium Channel Blockers , Potassium Channels/metabolism , Pyridines/pharmacology , Rabbits , Subcellular Fractions/metabolism , Tissue Distribution , Tritium , Vanadates/pharmacology , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...